Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA9849 | CA24256 | U.S. | 2001 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 122 |
| 2 | 3TC+AZT+IDV | 78 |
| 3 | 3TC+AZT+NFV | 35 |
| 4 | D4T+DDI+EFV | 39 |
| 5 | ABC+APV+EFV | 65 |
| 6 | ABC+EFV+NFV | 23 |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| K70R, M184V | D67G, K219E | K101P, K103N | K20R, K64R, D123E, R172K, Q207E, R211K, F214L | K11K*, T253TS |
| >CA24256| codons 1-298 PISPIETVPV*LKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV FAIRKKGSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPL DKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVI YQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDEKHQKEPPFLWMGYELHPDKWT VQPIVLPEKDSWSVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEE |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| D30N | L33F, N88D | N37NS, L63Q, A71V |
| >CA24257| codons 1-98 PQITLWQRPLVTIKIGGQLKEALLDTGADNTVFEEMSLPGRWKPKMIGGIGGFIKVRQYD QIQIEICGHKVIGTVLVGPTPVNIIGRDLLTQIGCTLN |
Integrase Sequence
| INIMajorDRMs | INIMinorDRMs | Polys | UnusualMuts |
| E11D, V31I, M50T, L101I, K111N, T124N, I208L, D256E | S283N |
| >CA125446| codons 1-288 FLDGIDKAQEDHEKYHSNWRAMASDFNLPPIVAKEIVASCDKCQLKGEATHGQVDCSPGI WQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYFILKLAGRWPVNTIHTDNGSN FTSNTVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAV FIHNFKRKGGIGGYSAGERIVDIIATDLQTKELQKQITKIQNFRVYYRDSRDPLWKGPAK LLWKGEGAVVIQDNSEIKVVPRRKAKIIRDYGKQMAGDDCVANRQDED |
References
| Author | Title | Citation |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |
| Melikian, GL | Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. | AAC, 2012 |